ambr® revolution Launch Show

Watch our video-streamed launch show event and receive insights into our revolutionary new products: ambr® 250 ht perfusion and ambr® crossflow

You are guided through the show and being introduced to the highlights of our innovative solutions. Furthermore, two development partners are sharing their experience during the development process of the systems.

The revolution starts now.

Sartorius Speakers and Development Partners

Stefan Schlack

Senior Vice President Marketing & Product Management,
Bioprocess Solutions at Sartorius Stedim Biotech is the host of our show and provides an overview of existing technologies, current innovations and an outlook for the bioprocess industry.

Barney Zoro

Product Manager at Sartorius Stedim Biotech will present the highlights of the ambr® 250 ht perfusion system.

Heather Nunn

Process Development Scientist, Pivotal Drug Substance Technologies at Amgen will describe the partnership that helped guide the development of the ambr® 250 ht perfusion.

John Betts

John Betts, Product Development Scientist at Sartorius Stedim Biotech will present the highlights of the ambr® crossflow system.

Jennifer Pollard

Senior Principle Scientist at MSD will explain the partnership between MSD and Sartorius and how it lead to the development of the ambr® crossflow.

ambr® crossflow

The High Throughput Solution For Parallel Screening

ambr® crossflow is a benchtop crossflow system for confirming the downstream manufacturability of biopharmaceuticals. It is a small-scale screening system with a minimum volume of 5 mL and a new range of ambr® CF filter cassettes with 10 cm² membrane area.

  • Study factors for manufacturability
  • Up to 16 automated, parallel trials
  • Lowest process volumes – 5ml recirculation volume

Find out more

ambr® 250 high throughput perfusion

The Fast Track to Intensified Cell Culture Processes

ambr® 250 high throughput perfusion is a parallel bioreactor system for rapid development of scalable perfusion processes using 100 – 250 mL single-use bioreactors and a fully automated liquid handling platform.

  • Typical range of hollow fibre cell retention applications
  • 24 fully single-use perfusion bioreactors in parallel
  • Lower production volumes and reduced cost of goods - optimization of intensified cell culture processes

Find out more